A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies.

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs PF 562271 (Primary)
  • Indications Head and neck cancer; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Mar 2012 Actual patients number changed from 106 to 99 as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual patient number (106) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top